Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Staghorn69on Feb 23, 2017 10:17pm
344 Views
Post# 25886832

RE:Wound Healing trial expected to commence H1 2017

RE:Wound Healing trial expected to commence H1 2017Wound Healing in H1...  Personally knowing first hand the severity of diabetic ulcer wounds, open sores, infections then amputations, loss of life quality and increased chance of infection, then inevitably an earlier painful death, I think Wound Healing is going to be the biggest thing this company does.  It is needed yesterday, everywhere.  Saves insurers Billions.  PL - time to get this to market NOW dude.  
Bullboard Posts